UNC Lineberger researchers uncover promising direction for the treatment of pancreatic cancers driven by KRAS mutation
In the journal Cancer Cell, UNC Lineberger researchers report findings of a promising strategy to treat KRAS-mutant pancreatic cancers. Preclinical studies showed promise for using a type of investigational drug that works by inhibiting the protein ERK, the last of a series of signals of a signaling pathway that drives drive abnormal growth of cells with KRAS mutations.
Researchers at UNC Lineberger Comprehensive Cancer Center found that breast cancer patients surveyed about their knowledge of breast reconstruction were only moderately informed about the procedure, and their knowledge of complications was low. The study, published in the journal Annals of Surgery, surveyed 126 breast cancer patients planning to undergo mastectomy at the N.C. Cancer Hospital.
Joseph DeSimone is the Chancellor’s Eminent Professor of Chemistry in the College of Arts and Sciences at the University of North Carolina at Chapel Hill and a member of UNC Lineberger. He will be honored in a ceremony at the White House.
In the journal Cell Reports, UNC Lineberger researchers report that when they removed Dicer from preclinical models of medulloblastoma, a common type of brain cancer in children, they found high levels of DNA damage in the cancer cells. The tumor cells were smaller, and also more sensitive to chemotherapy.